Health-related quality-of-life and treatment targets in myasthenia gravis

Kimiaki Utsugisawa, Shigeaki Suzuki, Yuriko Nagane, Masayuki Masuda, Hiroyuki Murai, Tomihiro Imai, Emiko Tsuda, Shingo Konno, Shunya Nakane, Yasushi Suzuki, Kazuo Fujihara, Norihiro Suzuki

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Introduction: The aim of this study was to determine factors affecting health-related quality of life (HRQOL) and to propose appropriate treatment targets for patients with myasthenia gravis (MG). Methods: We evaluated 640 consecutive patients with MG seen at 11 neurological centers. Two-year follow-up data were obtained for 282 patients. Correlations between detailed clinical factors and the Japanese version of the 15-item MG-specific QOL scale score were analyzed. Results: In a cross-sectional analysis of 640 MG patients, multivariate regression revealed that disease severity, as evaluated by the MG Composite (P<0.0001), total dose of oral prednisolone during the last year (P=0.002), and Cushingoid appearance index (P=0.0004), showed significant negative effects on HRQOL, but the quantitative MG score and current prednisolone dose did not. Conclusions: Achieving minimal manifestations (MM) status or better with prednisolone ≤5 mg/day was found to exert a major positive impact on HRQOL in both the cross-sectional and 2-year follow-up patient samples and can be recommended as a treatment target.

Original languageEnglish
Pages (from-to)493-500
Number of pages8
JournalMuscle and Nerve
Volume50
Issue number4
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Myasthenia Gravis
Quality of Life
Prednisolone
Therapeutics
Cross-Sectional Studies

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Utsugisawa, K., Suzuki, S., Nagane, Y., Masuda, M., Murai, H., Imai, T., ... Suzuki, N. (2014). Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle and Nerve, 50(4), 493-500. https://doi.org/10.1002/mus.24213

Health-related quality-of-life and treatment targets in myasthenia gravis. / Utsugisawa, Kimiaki; Suzuki, Shigeaki; Nagane, Yuriko; Masuda, Masayuki; Murai, Hiroyuki; Imai, Tomihiro; Tsuda, Emiko; Konno, Shingo; Nakane, Shunya; Suzuki, Yasushi; Fujihara, Kazuo; Suzuki, Norihiro.

In: Muscle and Nerve, Vol. 50, No. 4, 01.10.2014, p. 493-500.

Research output: Contribution to journalArticle

Utsugisawa, K, Suzuki, S, Nagane, Y, Masuda, M, Murai, H, Imai, T, Tsuda, E, Konno, S, Nakane, S, Suzuki, Y, Fujihara, K & Suzuki, N 2014, 'Health-related quality-of-life and treatment targets in myasthenia gravis', Muscle and Nerve, vol. 50, no. 4, pp. 493-500. https://doi.org/10.1002/mus.24213
Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Murai H, Imai T et al. Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle and Nerve. 2014 Oct 1;50(4):493-500. https://doi.org/10.1002/mus.24213
Utsugisawa, Kimiaki ; Suzuki, Shigeaki ; Nagane, Yuriko ; Masuda, Masayuki ; Murai, Hiroyuki ; Imai, Tomihiro ; Tsuda, Emiko ; Konno, Shingo ; Nakane, Shunya ; Suzuki, Yasushi ; Fujihara, Kazuo ; Suzuki, Norihiro. / Health-related quality-of-life and treatment targets in myasthenia gravis. In: Muscle and Nerve. 2014 ; Vol. 50, No. 4. pp. 493-500.
@article{d98c59cd6756480aa9921193f66292b0,
title = "Health-related quality-of-life and treatment targets in myasthenia gravis",
abstract = "Introduction: The aim of this study was to determine factors affecting health-related quality of life (HRQOL) and to propose appropriate treatment targets for patients with myasthenia gravis (MG). Methods: We evaluated 640 consecutive patients with MG seen at 11 neurological centers. Two-year follow-up data were obtained for 282 patients. Correlations between detailed clinical factors and the Japanese version of the 15-item MG-specific QOL scale score were analyzed. Results: In a cross-sectional analysis of 640 MG patients, multivariate regression revealed that disease severity, as evaluated by the MG Composite (P<0.0001), total dose of oral prednisolone during the last year (P=0.002), and Cushingoid appearance index (P=0.0004), showed significant negative effects on HRQOL, but the quantitative MG score and current prednisolone dose did not. Conclusions: Achieving minimal manifestations (MM) status or better with prednisolone ≤5 mg/day was found to exert a major positive impact on HRQOL in both the cross-sectional and 2-year follow-up patient samples and can be recommended as a treatment target.",
author = "Kimiaki Utsugisawa and Shigeaki Suzuki and Yuriko Nagane and Masayuki Masuda and Hiroyuki Murai and Tomihiro Imai and Emiko Tsuda and Shingo Konno and Shunya Nakane and Yasushi Suzuki and Kazuo Fujihara and Norihiro Suzuki",
year = "2014",
month = "10",
day = "1",
doi = "10.1002/mus.24213",
language = "English",
volume = "50",
pages = "493--500",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Health-related quality-of-life and treatment targets in myasthenia gravis

AU - Utsugisawa, Kimiaki

AU - Suzuki, Shigeaki

AU - Nagane, Yuriko

AU - Masuda, Masayuki

AU - Murai, Hiroyuki

AU - Imai, Tomihiro

AU - Tsuda, Emiko

AU - Konno, Shingo

AU - Nakane, Shunya

AU - Suzuki, Yasushi

AU - Fujihara, Kazuo

AU - Suzuki, Norihiro

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Introduction: The aim of this study was to determine factors affecting health-related quality of life (HRQOL) and to propose appropriate treatment targets for patients with myasthenia gravis (MG). Methods: We evaluated 640 consecutive patients with MG seen at 11 neurological centers. Two-year follow-up data were obtained for 282 patients. Correlations between detailed clinical factors and the Japanese version of the 15-item MG-specific QOL scale score were analyzed. Results: In a cross-sectional analysis of 640 MG patients, multivariate regression revealed that disease severity, as evaluated by the MG Composite (P<0.0001), total dose of oral prednisolone during the last year (P=0.002), and Cushingoid appearance index (P=0.0004), showed significant negative effects on HRQOL, but the quantitative MG score and current prednisolone dose did not. Conclusions: Achieving minimal manifestations (MM) status or better with prednisolone ≤5 mg/day was found to exert a major positive impact on HRQOL in both the cross-sectional and 2-year follow-up patient samples and can be recommended as a treatment target.

AB - Introduction: The aim of this study was to determine factors affecting health-related quality of life (HRQOL) and to propose appropriate treatment targets for patients with myasthenia gravis (MG). Methods: We evaluated 640 consecutive patients with MG seen at 11 neurological centers. Two-year follow-up data were obtained for 282 patients. Correlations between detailed clinical factors and the Japanese version of the 15-item MG-specific QOL scale score were analyzed. Results: In a cross-sectional analysis of 640 MG patients, multivariate regression revealed that disease severity, as evaluated by the MG Composite (P<0.0001), total dose of oral prednisolone during the last year (P=0.002), and Cushingoid appearance index (P=0.0004), showed significant negative effects on HRQOL, but the quantitative MG score and current prednisolone dose did not. Conclusions: Achieving minimal manifestations (MM) status or better with prednisolone ≤5 mg/day was found to exert a major positive impact on HRQOL in both the cross-sectional and 2-year follow-up patient samples and can be recommended as a treatment target.

UR - http://www.scopus.com/inward/record.url?scp=84922479558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922479558&partnerID=8YFLogxK

U2 - 10.1002/mus.24213

DO - 10.1002/mus.24213

M3 - Article

VL - 50

SP - 493

EP - 500

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -